Trial Profile

A Prospective, Randomized, Active Controlled, Parallel Group, Multi-center Trial to Assess the Efficacy and Safety of Mycophenolate Mofetil (MMF) in Inducing Response and Maintaining Remission in Subjects With Lupus Nephritis.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mycophenolate mofetil (Primary) ; Azathioprine; Cyclophosphamide; Prednisolone
Indications Lupus nephritis
Focus Registrational; Therapeutic Use
Acronyms ALMS
Sponsors Roche

09 May 2024 According to Aurinia Pharmaceuticals media release, data from the study were study at at the annual Congress of Clinical Rheumatology (CCR) East 2024 taking place in Destin, FL, May 9-12.
15 Nov 2023 Results assessing to compare and analyze the safety and efficacy data in propensity-matched patients from the ALMS (n=96) and AURORA 1 (n=96), presented at the ACR Convergence 2023.
16 Jul 2010 Status changed from recruiting to completed as reported by Roche.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com